CF
VERV

Corebridge Financial’s Verve Therapeutics VERV Stock Holding History

Corebridge Financial’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,803
Closed -$159K – 2695
2025
Q1 		$159K Sell
34,803
-517
-1% -$3.46K ﹤0.01% 2205
2024
Q4 		$199K Sell
35,320
-2,665
-7% -$15K ﹤0.01% 2190
2024
Q3 		$184K Sell
37,985
-235
-0.6% -$1.36K ﹤0.01% 2272
2024
Q2 		$187K Buy
+38,220
New +$240K ﹤0.01% 2240

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Corebridge Financial's VERV Position: Q2 2025 in Review

Corebridge Financial sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 34,803 shares — an estimated $159K sold.

Corebridge Financial first reported a position in VERV in Q2 2024 and held it in 4 quarters. The position peaked at $199K in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Corebridge Financial reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 34,803 Verve Therapeutics shares in Q2 2025, an estimated $159K.
  • Corebridge Financial first reported a position in Verve Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Verve Therapeutics position peaked at $199K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.